FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

 OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                       
1. Name and Address of Reporting Person * Akdamar Erol R 2. Date of Event Requiring Statement (MM/DD/YYYY)
1/1/2023 

 3. Issuer Name and Ticker or Trading Symbol HCA Healthcare, Inc. [HCA]
(Last)        (First)        (Middle)
ONE PARK PLAZA		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Group President /
(Street)
NASHVILLE, TN 37203      
(City)              (State)              (Zip)
 5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  37726  D   
Common Stock  60000  I  By LLC 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Right   (1) 11/6/2023  Common Stock  9000  $45.30  D   
Stock Appreciation Right   (2) 2/5/2024  Common Stock  14500  $47.97  D   
Stock Appreciation Right   (3) 2/5/2024  Common Stock  12325  $47.97  D   
Stock Appreciation Right   (4) 2/4/2025  Common Stock  20000  $68.96  D   
Stock Appreciation Right   (5) 1/29/2026  Common Stock  16440  $69.58  D   
Stock Appreciation Right   (6) 2/1/2027  Common Stock  17430  $81.96  D   
Stock Appreciation Right   (7) 1/31/2028  Common Stock  25160  $101.16  D   
Stock Appreciation Right   (8) 1/30/2029  Common Stock  14670  $139.06  D   
Stock Appreciation Right   (9) 1/29/2030  Common Stock  16910  $145.24  D   
Stock Appreciation Right   (10) 2/3/2031  Common Stock  12820  $173.12  D   
Stock Appreciation Right   (11) 1/28/2032  Common Stock  8490  $236.61  D   

Explanation of Responses:
(1)  The stock appreciation rights vested in four equal annual installments beginning on November 6, 2014.
(2)  The stock appreciation rights vested in four equal annual installments beginning on February 5, 2015.
(3)  The stock appreciation rights vested at the end of fiscal years 2014, 2015, 2016 and 2017 based upon the achievement of certain annual EBITDA performance targets.
(4)  The stock appreciation rights vested in four equal annual installments beginning on February 4, 2016.
(5)  The stock appreciation rights vested in four equal annual installments beginning on January 29, 2017.
(6)  The stock appreciation rights vested in four equal annual installments beginning on February 1, 2018.
(7)  The stock appreciation rights vested in four equal annual installments beginning on January 31, 2019.
(8)  The stock appreciation rights vest in four equal annual installments beginning on January 30, 2020.
(9)  The stock appreciation rights vest in four equal annual installments beginning on January 29, 2021.
(10)  The stock appreciation rights vest in four equal annual installments beginning on February 3, 2022.
(11)  The stock appreciation rights vest in four equal annual installments beginning on January 28, 2023.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Akdamar Erol R
ONE PARK PLAZA
NASHVILLE, TN 37203

Group President

Signatures
/s/ Kevin A. Ball, Attorney-in-Fact 1/11/2023
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
HCA Healthcare (NYSE:HCA)
Historical Stock Chart
Von Mär 2023 bis Mär 2023 Click Here for more HCA Healthcare Charts.
HCA Healthcare (NYSE:HCA)
Historical Stock Chart
Von Mär 2022 bis Mär 2023 Click Here for more HCA Healthcare Charts.